Liquid Biopsies for Lung Cancer: Vision 2020

Liquid biopsies are non-invasive tests, most commonly blood-based, that detect cancer through the identification of shed genetic material into circulation. The technology holds the promise of a non-invasive ‘Swiss army knife’ of diagnostics, with the potential for utility across screening, diagnosis, monitoring, treatment selection, and resistance detection to spare patients unnecessary procedures.

 

Although liquid biopsies encompass a range of possible targets including circulating tumor DNA (ctDNA), circulating tumor cells and exosomes, ctDNA liquid biopsies have been most swiftly adopted in clinical practice for non-small cell lung cancer.

 

In this white paper, our CEO and Medical Director, Dr. Min-Han Tan, and our CTO, Dr. Yukti Choudhury, share their expert perspectives on:

 

  • Liquid Biopsies: From Single Genes to Multiple Genes
  • How Liquid Biopsy and Immunotherapy Can Collaborate?
  • Clinical Interpretation: Pearls and Pitfalls
  • Lung Cancer Screening by a Blood Test: The Promise
  • Vision 2020: The Future

 

Contact us at [email protected] if you have any questions about the white paper.

 

Need Help?